Patients completing neoadjuvant chemotherapy, breast cancer during pregnancy, T2 or N1 HR+/HER2- tumors, and triple-negative or HER2+ patients range from high to intermediate surgical priority, taking into consideration the COVID-19 urgency setting and alternative treatment options [8,9,10,11,12,14,15,18,19]. This evidence concerns the gene ERBB2 and breast cancer.